Population impact of Vi capsular polysaccharide vaccine

M. Imran Khan, R. Leon Ochiai, John D. Clemens

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)


Development of a safe and efficacious vaccine against typhoid fever has been the mainstay of enteric vaccinology since production of the first parenteral whole-cell typhoid vaccine in 1896. The new-generation Vi polysaccharide single-dose injectable typhoid vaccine developed in the 1980s is widely used in countries where it is locally produced, such as China, and in travelers from industrialized countries to typhoid-endemic settings. However, Vi vaccine use is limited to private practice at a small scale by residents of high-burden countries such as India, Pakistan and Bangladesh. Recognition of the public health importance of typhoid fever prevention has significantly increased due to the emergence of antimicrobial-resistant strains of Salmonella enterica serovar Typhi in recent years. Recent evidence of herd protection conferred by the Vi vaccine has highlighted the significance of the vaccines effects beyond the vaccinated population. The large-scale use of this vaccine can yield protective benefits to a larger population and can reduce the epidemiologic and economic burden of typhoid fever in endemic countries.

Original languageEnglish
Pages (from-to)485-496
Number of pages12
JournalExpert Review of Vaccines
Issue number5
Publication statusPublished - May 2010
Externally publishedYes


  • Effectiveness
  • Efficacy
  • Fever
  • Salmonella Typhi
  • Typhoid
  • Vi polysaccharide


Dive into the research topics of 'Population impact of Vi capsular polysaccharide vaccine'. Together they form a unique fingerprint.

Cite this